HALO : Analysis & Opinions

  1. AbbVie Ends Halozyme Enhanze Development Program (HALO, ABBV)

    November 22, 2016
    AbbVie ended a drug development partnership with Halozyme Therapeutics after a failed study.
  2. Halozyme 3Q Loss $29M, or 23 Cents a Share (HALO)

    November 9, 2016
    Halozyme reported a third-quarter loss of 23 cents a share, beating analyst projections.
  3. How Halozyme Uses Enzymes to Deliver Drugs (HALO)

    September 19, 2016
    Halozyme's use of enzymes to deliver drugs under the skin could win longterm, but profits may be years away
Trading Center